XML 67 R45.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Stock Incentive Plans (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
Summary of Stock-Based Compensation | The following table is a summary of stock-based compensation for the years ended December 31, 2023, 2022 and 2021:
In millions | 2023 |  | 2022 |  | 2021
Restricted stock units and performance stock units | $ | 497 |  |  | $ | 369 |  |  | $ | 404 |
Stock options and stock appreciation rights (“SARs”) (1) | 91 |  |  | 78 |  |  | 80 |
Total stock-based compensation (2) | $ | 588 |  |  | $ | 447 |  |  | $ | 484 |
_____________________________________________ (1)Includes the Employee Stock Purchase Plan (“ESPP”). (2)Total stock-based compensation for the year ended December 31, 2023 included $71 million and $72 million of post-combination expense associated with replacement equity awards granted in connection with the Oak Street Health and Signify Health acquisitions, respectively.
Restricted Stock Unit and Performance Stock Unit Activity | The following table is a summary of the restricted stock unit and performance stock unit activity for the year ended December 31, 2023:
In thousands, except weighted average grant date fair value | Units |  | Weighted Average Grant Date Fair Value
Outstanding at beginning of year, nonvested | 12,681 |  |  | $ | 80.25 |
Granted (1) | 13,918 |  |  | $ | 71.06 |
Vested (2) | (7,346) |  |  | $ | 71.46 |
Forfeited | (2,259) |  |  | $ | 71.78 |
Outstanding at end of year, nonvested | 16,994 |  |  | $ | 77.65 |
_____________________________________________ (1)Includes 3.9 million and 1.8 million restricted stock replacement equity awards granted in connection with the Oak Street Health and Signify Health acquisitions, respectively. (2)Vested performance stock units have been included at target level performance. Based on actual performance, the number of restricted stock units and performance stock units vested during the year ended December 31, 2023 was 7.8 million.
Summary of Stock Option and SAR Activity | The following table is a summary of stock option and SAR activity that occurred for the years ended December 31, 2023, 2022 and 2021:
In millions | 2023 |  | 2022 |  | 2021
Cash received from stock options exercised (including ESPP) | $ | 277 |  |  | $ | 551 |  |  | $ | 549 |
Payments for taxes for net share settlement of equity awards | 181 |  |  | 370 |  |  | 168 |
Intrinsic value of stock options and SARs exercised | 31 |  |  | 118 |  |  | 105 |
Fair value of stock options and SARs vested | 227 |  |  | 219 |  |  | 224 |
Schedule of Valuation Assumptions | The fair value of each stock option is estimated using the Black-Scholes option pricing model based on the following assumptions at the time of grant:
| 2023 |  | 2022 |  | 2021
Dividend yield (1) | 3.27 | % |  | 2.18 | % |  | 2.68 | %
Expected volatility (2) | 28.15 | % |  | 27.34 | % |  | 27.10 | %
Risk-free interest rate (3) | 3.55 | % |  | 2.46 | % |  | 1.13 | %
Expected life (in years) (4) | 5.9 |  | 6.3 |  | 6.3
Weighted-average grant date fair value | $ | 21.78 |  |  | $ | 24.15 |  |  | $ | 14.57 |
_____________________________________________ (1)The dividend yield is based on annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date. (2)The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits. (3)The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued. (4)The expected life represents the number of years the options are expected to be outstanding from grant date based on historical option or SAR holder exercise experience.
Schedule of Stock Options and Stock Appreciation Rights Award Activity | The following table is a summary of the Company’s stock option and SAR activity for the year ended December 31, 2023:
In thousands, except weighted average exercise price and remaining contractual term | Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value
Outstanding at beginning of year | 15,040 |  |  | $ | 73.15 |  |  |  |  |
Granted (1) | 4,595 |  |  | $ | 63.06 |  |  |  |  |
Exercised | (1,652) |  |  | $ | 50.03 |  |  |  |  |
Forfeited | (624) |  |  | $ | 76.74 |  |  |  |  |
Expired | (2,233) |  |  | $ | 102.47 |  |  |  |  |
Outstanding at end of year | 15,126 |  |  | $ | 68.13 |  |  | 5.21 |  | $ | 203,645 |
Exercisable at end of year | 7,785 |  |  | $ | 63.64 |  |  | 3.35 |  | 130,509 |
Vested at end of year and expected to vest in the future | 14,793 |  |  | $ | 67.95 |  |  | 5.14 |  | 201,439 |
_____________________________________________ (1)Includes 1.4 million stock option replacement equity awards granted in connection with the Signify Health acquisition.
Schedule ESPP Valuation Assumptions | The following table is a summary of the assumptions used to value the ESPP awards for the years ended December 31, 2023, 2022 and 2021:
| 2023 |  | 2022 |  | 2021
Dividend yield (1) | 1.54 | % |  | 1.12 | % |  | 1.34 | %
Expected volatility (2) | 25.61 | % |  | 23.54 | % |  | 25.27 | %
Risk-free interest rate (3) | 5.17 | % |  | 1.42 | % |  | 0.08 | %
Expected life (in years) (4) | 0.5 |  | 0.5 |  | 0.5
Weighted-average grant date fair value | $ | 14.26 |  |  | $ | 16.25 |  |  | $ | 12.55 |
_____________________________________________ (1)The dividend yield is calculated based on semi-annual dividends paid and the fair market value of CVS Health Corporation stock at the grant date. (2)The expected volatility is estimated based on the historical volatility of CVS Health Corporation’s daily stock price over the previous six month period. (3)The risk-free interest rate is selected based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP purchases (i.e., six months). (4)The expected life is based on the semi-annual purchase period.

X
- Definition Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A + Details
Name: | us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the changes in outstanding nonvested shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration